{beta}-Cell function following human islet transplantation for type 1 diabetes |
| |
Authors: | Rickels Michael R Schutta Mark H Markmann James F Barker Clyde F Naji Ali Teff Karen L |
| |
Institution: | University of Pennsylvania School of Medicine, Division of Endocrinology, Diabetes,Metabolism, 778 Clinical Research Building, 415 Curie Blvd., Philadelphia, PA 19104-6149, USA. mrrickels@aol.com |
| |
Abstract: | Islet transplantation can provide metabolic stability for patients with type 1 diabetes; however, more than one donor pancreas is usually required to achieve insulin independence. To evaluate possible mechanistic defects underlying impaired graft function, we studied five subjects at 3 months and four subjects at 12 months following intraportal islet transplantation who had received comparable islet equivalents per kilogram (12,601 +/- 1,732 vs. 14,384 +/- 2,379, respectively). C-peptide responses, as measures of beta-cell function, were significantly impaired in both transplant groups when compared with healthy control subjects (P < 0.05) after intravenous glucose (0.3 g/kg), an orally consumed meal (600 kcal), and intravenous arginine (5 g), with the greatest impairment to intravenous glucose and a greater impairment seen in the 12-month compared with the 3-month transplant group. A glucose-potentiated arginine test, performed only in insulin-independent transplant subjects (n = 5), demonstrated significant impairments in the glucose-potentiation slope (P < 0.05) and the maximal response to arginine (AR(max); P < 0.05), a measure of beta-cell secretory capacity. Because AR(max) provides an estimate of the functional beta-cell mass, these results suggest that a low engrafted beta-cell mass may account for the functional defects observed after islet transplantation. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|